Is NAC Oxidative Stress Randomized Trial safe?

Updated July 2026

Quick Answer

NAC Oxidative Stress Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Preeclampsia with severe features represents an escalation of preeclampsia severity and is associated with a higher risk of adverse maternal and fetal outcomes [,].

Key Takeaways

  • 01Preeclampsia with severe features represents an escalation of preeclampsia severity and is associated with a higher risk of adverse maternal and fetal outcomes [,]. [Okunade Kehinde S. (2026)]
  • 02While certain interventions, such as low-dose aspirin prophylaxis [] in high-risk women, have shown some efficacy in reducing the risk of preeclampsia, there remains a need for additional measures to prevent the development of severe disease in women with early-onset preeclampsia, particularly in resource-constrained settings where the burden of disease is greatest []. [Okunade Kehinde S. (2026)]
  • 03Currently, the only cure for preeclampsia is delivery of the fetus and placenta [,] however, this is commonly associated with iatrogenic preterm delivery. [Okunade Kehinde S. (2026)]
  • 041 2 3 4 2 5 6 Preeclampsia is a progressive multisystemic complication of pregnancy characterized by hypertension and often proteinuria, typically occurring after 20 weeks of gestation []. [Okunade Kehinde S. (2026)]
The current Migaku evidence database contains 2 reusable source documents for NAC Oxidative Stress Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Preeclampsia with severe features represents an escalation of preeclampsia severity and is associated with a higher risk of adverse maternal and fetal outcomes [,]. [Okunade Kehinde S. (2026); evidence level 2] - While certain interventions, such as low-dose aspirin prophylaxis [] in high-risk women, have shown some efficacy in reducing the risk of preeclampsia, there remains a need for additional measures to prevent the development of severe disease in women with early-onset preeclampsia, particularly in resource-constrained settings where the burden of disease is greatest []. [Okunade Kehinde S. (2026); evidence level 2] - Currently, the only cure for preeclampsia is delivery of the fetus and placenta [,] however, this is commonly associated with iatrogenic preterm delivery. [Okunade Kehinde S. (2026); evidence level 2] - 1 2 3 4 2 5 6 Preeclampsia is a progressive multisystemic complication of pregnancy characterized by hypertension and often proteinuria, typically occurring after 20 weeks of gestation []. [Okunade Kehinde S. (2026); evidence level 2] - 1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults (). [Wang Xiaolan (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. A randomized controlled trial of N-acetylcysteine in the treatment of early-onset preeclampsia: Study Protocol
  2. Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults